"Crescendo has built a strong and growing position in the rheumatoid arthritis diagnostic market, and I believe Myriad will enable us to move to the next level in terms of scale and growth," said William Hagstrom, president and CEO of Crescendo Bioscience. "We envision multiple opportunities over thacquisition during its second fiscal quarter earnings call on Tuesday, February 4, 2014 at 4:30 pm EST. Participating on the call will be Peter Meldrum, president and CEO; William Hagstrom, president of Crescendo Bioscience; Mark Capone, president of Myriad Genetic Laboratories; and James Evans, CFO.
William Hagstrom (1952-1956), Ed Stoessel (1961-1965), Hal Wadleigh (1964-1966), Jack Nelson (1966-1968), Dennis Stanczyk (1959-1963), Elie Chouinard (1956-1960)